In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae
about
Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin.Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice.In vitro and in vivo activities of azithromycin, a new azalide antibiotic, against chlamydiaThe next generation: fluoroquinolones in the management of acute lower respiratory infection in adultsAntibiotics effects in a rabbit model of Chlamydia pneumoniae-induced atherosclerosis.Antibiotics in the prevention and treatment of coronary heart disease.Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patientsCommonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis.Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin.Relevance of Chlamydia pneumoniae murine pneumonitis model to evaluation of antimicrobial agents.Single-dose intrapulmonary pharmacokinetics of azithromycin, clarithromycin, ciprofloxacin, and cefuroxime in volunteer subjects.In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.In vitro activity of trovafloxacin against Chlamydia pneumoniaeChlamydia pneumoniae (TWAR).In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.In vitro activity of azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae.A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease.Antibiotic susceptibility of Waddlia chondrophila in Acanthamoeba castellanii amoebae.A novel combination approach of human polyclonal IVIG and antibiotics against multidrug-resistant Gram-positive bacteriaIn vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.Influence of clarithromycin on early atherosclerotic lesions after Chlamydia pneumoniae infection in a rabbit model.An open, comparative pilot study of thiamphenicol glycinate hydrochloride vs clarithromycin in the treatment of acute lower respiratory tract infections due to Chlamydia pneumoniae.Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model.Rationale and design of a secondary prevention trial of antibiotic use in patients after myocardial infarction: the WIZARD (weekly intervention with zithromax [azithromycin] for atherosclerosis and its related disorders) trial.In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae.Can an antibiotic (macrolide) prevent Chlamydia pneumoniae-induced atherosclerosis in a rabbit model?In vitro activities of gemifloxacin (SB 265805, LB20304) against recent clinical isolates of Chlamydia pneumoniae.In vitro activities of azithromycin and ofloxacin against Chlamydia pneumoniae in a continuous-infection modelIn vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.Levofloxacin and sparfloxacin: new quinolone antibiotics.In vitro susceptibility of Chlamydia pecorum to macrolides, tetracyclines, quinolones and beta-lactam.Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia.Chlamydia pneumoniae respiratory infections among patients infected with the human immunodeficiency virus.Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations.In vitro activities of azithromycin, clarithromycin, and other antibiotics against Chlamydia pneumoniae.Chlamydia pneumoniae and chronic pharyngitis.Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.
P2860
Q33598839-E30A562D-3E8B-4F33-B201-C0DDBD502DCCQ33756547-1730AB6C-DDB3-4F32-8C51-54973014C2B1Q33760662-92F18F7E-0F41-4BC8-96CE-E96A30D667FAQ33801878-1E334377-2FE4-491E-9478-BE97DBFEF062Q33935083-DE760EAE-A768-4C34-8549-4B52B8589548Q33935098-BA948C6A-DE9C-4158-B8EA-F5B4BCD0CDB0Q33976830-4E3E9B87-3BD2-4953-9E18-2678AB2633A8Q34437719-EFE79313-342E-47D8-A37F-BA5BAACFED05Q35110637-7C203089-746A-47CA-A779-8283F39C46B7Q35111440-C3A6A7C4-40EB-416F-80B7-336D145875BAQ35118114-A4E63F58-27BD-49F4-A1E3-DACED74C494EQ35125517-1D9A6A6D-A4BD-4D1A-93D7-D7B8E8B790FFQ35136707-F891927C-17BA-4D95-AB56-07190DFD614EQ35138146-863B9FE2-B032-4E0D-AE0C-8312267BC229Q35138264-E99F28C3-A18D-4F3F-9C63-EE463B935902Q35367697-115EA9F9-E9A4-4F80-B150-B90A26821482Q35811943-62C46891-3F71-42F7-8523-D326B33F2E2CQ35818615-97B7384B-0895-41A3-A960-6C2F80D53E3FQ36035081-D61B6B6F-1608-4147-A62C-8370FE36692DQ37204183-464A2668-A72A-43B2-8F4B-8F8FECD69482Q37496502-86AFE9A3-38CE-41D0-BF24-E33F046CCCC1Q37870051-E08C6A94-BD5E-4193-8C87-E61A57BD8E8AQ37871579-B1BA665C-6C3D-4B5B-8062-C91F2D6F7D7DQ37871587-5EB6AAD3-0224-44F4-ACAD-DC70A85235D2Q37872800-DFDF6BDE-4026-48E0-BB96-BC43F34E2FB6Q37876312-97433662-D044-4A12-8903-37C9CB6447F2Q37876885-FADE1A2A-DC67-42F1-B953-1B55699DF688Q37877470-4F5FA45E-669E-4962-ABE1-402C6759A646Q37877492-E67B17C0-35B5-4824-8633-1D9EB5185950Q37877849-4C1F4DED-890B-474D-B8D1-0E6BFA224141Q37880865-23D29EE2-2119-41A4-86F1-DD53CDA55853Q37881176-9D35CA11-B889-40C4-AD9D-4060FD192B3CQ37881273-7A648342-23CC-4D8E-87B3-D2BBA67ECC53Q37881312-DB6F16BF-057C-4B82-B739-8AAFADE0AF6FQ37881682-F604D699-E1F8-483E-BC07-527C4B216BBEQ37881880-DC5995CE-6AF2-4423-A19E-D59129E81B5CQ37883672-B5E7A00A-B9E4-4F94-92BF-0C24D9755100Q37884244-4B52EEC2-9785-457B-A867-5901D467AFDEQ37887835-D1E2AABE-94E0-412B-B2CD-61E082EF0714Q37888465-002ADFC7-C820-4194-BA6C-9DF98F829AE8
P2860
In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年学术文章
@wuu
1992年学术文章
@zh-cn
1992年学术文章
@zh-hans
1992年学术文章
@zh-my
1992年学术文章
@zh-sg
1992年學術文章
@yue
1992年學術文章
@zh
1992年學術文章
@zh-hant
name
In vitro activities of azithro ...... s against Chlamydia pneumoniae
@ast
In vitro activities of azithro ...... s against Chlamydia pneumoniae
@en
type
label
In vitro activities of azithro ...... s against Chlamydia pneumoniae
@ast
In vitro activities of azithro ...... s against Chlamydia pneumoniae
@en
prefLabel
In vitro activities of azithro ...... s against Chlamydia pneumoniae
@ast
In vitro activities of azithro ...... s against Chlamydia pneumoniae
@en
P2093
P2860
P356
P1476
In vitro activities of azithro ...... s against Chlamydia pneumoniae
@en
P2093
Hammerschlag MR
P2860
P304
P356
10.1128/AAC.36.7.1573
P407
P577
1992-07-01T00:00:00Z